Stockscreener 앱 받기
49.98
0.34%
-0.17
시간 외 거래:
50.47
0.49
+0.98%
Exelixis Inc 주식(EXEL)의 최신 뉴스
EXEL (NASDAQ: EXEL) executive files Form 144 to sell compensation shares - Stock Titan
Have Exelixis Insiders Been Selling Stock? - simplywall.st
Avoiding Lag: Real-Time Signals in (EXEL) Movement - Stock Traders Daily
Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL) - Seeking Alpha
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 - Investing.com India
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near - Barchart.com
Insider Sell: Patrick Haley Sells 32,110 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 By Investing.com - Investing.com South Africa
Exelixis EVP, Commercial Sold Shares Worth Over $1.5M - TradingView
Exelixis (EXEL) EVP Haley sells 32,110 shares, retains 357,638 - Stock Titan
Exelixis (EXEL): 12 Best Low Priced Growth Stocks to Invest In Now - Insider Monkey
How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration - Sahm
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types - BioSpace
Exelixis Inc stock (US30161Q1040): oncology player in focus after latest earnings and pipeline updat - AD HOC NEWS
Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration - Yahoo Finance
EXEL News | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha? - Trefis
EXEL (EXEL) Rule 144 filing: 32,110 issuer-held shares vested - Stock Titan
EXEL: Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy - TradingView
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - Yahoo Finance
Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing - Moomoo
Exelixis EVP and CFO Senner sells $1.75m in company stock By Investing.com - Investing.com South Africa
Exelixis EVP and CFO Senner sells $1.75m in company stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock By Investing.com - Investing.com South Africa
Exelixis (NASDAQ: EXEL) CEO reports share gifts and tax withholding - Stock Titan
Exelixis (NASDAQ: EXEL) CFO sells shares, reports tax withholding and large remaining stake - Stock Titan
Exelixis (EXEL) EVP reports 33,265-share tax withholding, 389,748-share stake - Stock Titan
Insider sale: Exelixis (EXEL) SVP and General Counsel sells 6,625 shares - Stock Titan
Exelixis (NASDAQ: EXEL) EVP Dana Aftab reports tax-withholding of 30,578 shares - Stock Titan
Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial - Moomoo
Exelixis partners with Merck for colorectal cancer trial By Investing.com - Investing.com South Africa
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer - BioSpace
Merck (MRK) Partners with Exelixis in Clinical Trial for Colorec - GuruFocus
Exelixis partners with Merck for colorectal cancer trial - Investing.com
EXEL Stock Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Proposed resale of vested restricted shares by EXEL (NASDAQ: EXEL) - Stock Titan
[144] EXELIXIS, INC. SEC Filing - Stock Titan
Exelixis, Inc.Common Stock (NQ: EXEL - The Chronicle-Journal
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Prospects Amidst Analyst Divergence - DirectorsTalk Interviews
Stephens Investment Management Group LLC Buys 28,265 Shares of Exelixis, Inc. $EXEL - MarketBeat
Thrivent Financial for Lutherans Increases Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus - AD HOC NEWS
Prediction: This stock could double by 2031 - MSN
48,292 Shares in Exelixis, Inc. $EXEL Purchased by Convergence Investment Partners LLC - MarketBeat
Prediction: This Stock Could Double By 2031 - Yahoo Finance
Prediction: This Stock Could Double By 2031 - The Motley Fool
0.98%
0.12%
자본화:
|
볼륨(24시간):